transforming women's health with an innovative solution
Aspira Women's Health is led by an experienced team of business, medical and scientific professionals with a passion for improving health outcomes for women.
Our Mission
Aspira Women's Health is helping transform women’s health with the discovery, development, and utilization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. Our FDA-cleared products OVA1® and OVERA® detect the risk of ovarian malignancy in women with adnexal masses. Recently launched, Aspira GenetiXSM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of experience in ovarian cancer risk assessment, Aspira Women's Health has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans.
We are committed to the discovery, development, and utilization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women.
Aspira Women's Health Corporate Overview
Aspira Women's Health CEO Valerie Palmieri joined Proactive at the Biotech Showcase 2020 in San Francisco. Click here to watch the interview.
Latest News & Events
-
April 14, 2021
I have a pelvic mass. What should I do next?
Read More -
March 25, 2021
Aspira Women’s Health Reports Fourth Quarter and Full Year 2020 Financial Results
Read More -
March 25, 2021
Aspira Women’s Health, Inc. Announces an Agreement for the Development and Commercialization of an Early-Detection Test for Identification of Ovarian Cancer
Read More
Aspira Women's Health’s Corporate Vision
To contribute to the advancement of women’s health by providing innovative methods to detect, monitor and manage the treatment of gynecologic disease – starting with ovarian cancer. We have expanded our corporate strategy by preforming innovative research, increasing our product offerings, diversifying our delivery channels, and expanding partnerships.
Committee Members
Below is a summary of our committee membership information.
| Audit Committee | Compensation Committee | Nomination and Corporate Governance Committee | |
|---|---|---|---|
| James T. LaFrance (Board Chairperson) | |||
| Valerie Palmieri | |||
| Veronica G.H. Jordan, Ph.D. | Member | Chairperson | |
| David Schreiber | Chairperson | Member | |
| Nicole Sandford | Member | Member | |
| Sandra Brooks, MD | Member |
Analyst Coverage
Aspira Women's Health is followed by the analysts listed below. Please note that any opinions, estimates or forecasts regarding Aspira Women's Health’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Aspira Women's Health or its management. Aspira Women's Health does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
- Brookline Capital Markets
- William Blair & Company
- Cantor Fitzgerald
SEC Filings
-
Corporate Headquarters
12117 Bee Caves Road, Building III, Suite 100 Austin, TX 78738
Tel: 512.519.0400
Fax: 512.439.6908 -
Investor Relations
Ashley R. Robinson,
LifeSci Advisors LLC.
Tel: 617.430.7577
Email: [email protected]